Get Nobivac ®

EDGE™ DAPPv+L4

Provides proven protection against several common viruses and enhanced quality in leptospirosis protection by using the VacciPure™ filtration process.

NOBIVAC EDGE™ DAPPV+L4 PROVIDES PROTECTION TO HELP KEEP DOGS HEALTHY IN A 0.5 ML VACCINE

Canine Distemper Virus, Canine Adenovirus 2, Canine Parainfluenza Virus, Canine Parvovirus (modified live viruses), Leptospira Canicola- Grippotyphosa-Icterohaemorrhagiae-Pomona (inactivated bacterin).

PRODUCT LABEL
  • Protects against all known strains of canine parvovirus (CPV), including CPV-2c2,3
  • The only leptospirosis vaccine to protect and defend against mortality and urinary shedding
  • Prevented mortality caused by 4 virulent Leptospira serovars1
  • Protects against adenovirus type 1 that causes hepatitis in dogs
  • Provides disease coverage for commonly spread canine viruses, distemper, adenovirus type 1 (hepatitis), parainfluenza and parvovirus, in 1 formula

INDICATIONS:

Effective for the vaccination against distemper, adenovirus type 1 (hepatitis), parainfluenza, parvovirus, L. canicola, L. icterohaemorrhagiae, L. pomona, or L. grippotyphosa.

Also effective against leptospiruria caused by L. canicola, L. icterohaemorrhagiae, L. pomona, or L. grippotyphosa.

Recommended for use in healthy dogs 6 weeks of age or older.

NOBIVAC EDGE™ DAPPV+L4 IS A SAFE CHOICE

  • Safety confirmed in 346-dog field study1
  • Proven safe across a variety of dog breeds and ages
  • Featuring an even higher level of quality due to VacciPure™ filtration

ADMINISTRATION AND DOSAGE

  • Subcutaneous injection
  • Two 0.5 mL doses given 2 to 4 weeks apart
  • Repeat at 2 to 4 week intervals until the dog is 12 weeks of age
  • The need for annual revaccination has not been established
  • Available in a 25 x 0.5 mL dose presentation

ALSO AVAILABLE IN OTHER FORMULATIONS

DISEASE INFORMATION

Professional Resources and Educational Materials

Keep your clinic and staff informed and aware of diseases and outbreaks.

View More Nobivac® Resources

References:

1. Data on file, Merck Animal Health. 

2. Larson LJ, Schultz RD. Do two current canine parvovirus type 2 and 2b vaccines provide protection against the new type 2c variant? Vet Ther. 2008;9(2):94–101. 

3. Schultz RD, Thiel B, Mukhtar E, Sharp P, Larson LJ. Age and long-term protective immunity in dogs and cats. J Comp Pathol. 2010;142 Suppl 1:S102–S108.

View All Nobivac References